GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells

GP‐2250, a novel anticancer agent, severely limits the energy metabolism, as demonstrated by the inhibition of hexokinase 2 and glyceraldehyde‐3‐phosphate dehydrogenase and a decrease of ATP. Rescue experiments with supplementary pyruvate or oxaloacetate demonstrated that a TCA cycle deficit largely...

Descripción completa

Detalles Bibliográficos
Autores principales: Majchrzak‐Stiller, Britta, Buchholz, Marie, Peters, Ilka, Waschestjuk, Daniel, Strotmann, Johanna, Höhn, Philipp, Hahn, Stephan, Braumann, Chris, Uhl, Waldemar, Müller, Thomas, Möhler, Hanns
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339077/
https://www.ncbi.nlm.nih.gov/pubmed/37390227
http://dx.doi.org/10.1111/jcmm.17825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339077/
https://www.ncbi.nlm.nih.gov/pubmed/37390227
http://dx.doi.org/10.1111/jcmm.17825

Ejemplares similares